Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-30T05:48:13.512Z Has data issue: false hasContentIssue false
  • English
  • Français

P0041 - Efficacy and tolerability of fluvoxamine in outpatients with anxiety disorders

Published online by Cambridge University Press:  16 April 2020

D. Lasic ,
J. Marinovic Curin ,
M. Zuljan Cvitanovic  and
T. Glavina
D. Lasic
Affiliation:
Psychiatry Clinic, Clinical Hospital Center, Split, Croatia
J. Marinovic Curin
Affiliation:
Psychiatry Clinic, Clinical Hospital Center, Split, Croatia
M. Zuljan Cvitanovic
Affiliation:
Psychiatry Clinic, Clinical Hospital Center, Split, Croatia
T. Glavina
Affiliation:
Psychiatry Clinic, Clinical Hospital Center, Split, Croatia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Prospective, three months study of efficacy and tolerability of fluvoxamine in outpatients with Anxiety disorders. The subjects were the patients older than 18 years of age, previously without therapy or treated with other psychopharmacological treatment, with diagnosis of Anxiety disorder (F40 to F49 according to ICD-10 Classification of Mental Disorder). Clinical efficacy was evaluated with Hamilton Anxiety Rating Scale HAM-A and Clinical Global Impression scales at baseline visit, after one month and after three months of fluvoxamine therapy. Side effects were recorded during the therapy.

Aim of the study:

Evaluation of efficacy and tolerability of fluvoxamine in outpatients with Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder).

Inclusion criteria:

Female and male outpatients older than 18 years of age treated in Psychiatry Clinic Clinical Hospital Center Split, previously without therapy or treated with other psychopharmacological treatment, to which one of the following Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder) was diagnosed.

Exclusion criteria

  1. - Hypersensitivity to fluvoxamine

  2. - Pregnancy and lactation

  3. - Hepatic or kidney insufficiently

  4. - Unstable epilepsy

  5. - Discontinuation of the treatment with irreversible monoamine oxidize inhibitors less than 14 days prior to introduction of fluvoxamine therapy

  6. - Discontinuation of moclobemide therapy less than one day prior to introduction of fluvoxamine therapy.

Statistical Methods:

Descriptive statistics was used for the analysis of demographic data and incidence of adverse events.

Repeated Measures Analysis of Variance was used for data analysis (Statistical software SPSS).

Statistical significance was defined as p≤0,05.

Type
Poster Session II: Antidepressants
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S204
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.